J P Morgan Chase & Co reaffirmed their overweight rating on shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) in a report released on Tuesday, Marketbeat reports. J P Morgan Chase & Co currently has a $46.00 price target on the stock, up from their prior price target of $44.00.
A number of other equities analysts have also issued reports on GBT. BidaskClub upgraded shares of Global Blood Therapeutics from a sell rating to a hold rating in a research report on Saturday, August 5th. Oppenheimer Holdings, Inc. assumed coverage on shares of Global Blood Therapeutics in a research report on Friday, August 4th. They issued an outperform rating and a $53.00 target price for the company. ValuEngine upgraded shares of Global Blood Therapeutics from a sell rating to a hold rating in a research report on Saturday, June 10th. Janney Montgomery Scott assumed coverage on shares of Global Blood Therapeutics in a research report on Monday, May 1st. They issued a buy rating and a $37.00 target price for the company. Finally, Wedbush reiterated an outperform rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research report on Tuesday, May 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of Buy and an average target price of $50.75.
Global Blood Therapeutics (NASDAQ:GBT) opened at 28.55 on Tuesday. Global Blood Therapeutics has a 12 month low of $13.35 and a 12 month high of $41.15. The stock’s market capitalization is $1.25 billion. The firm’s 50-day moving average is $28.14 and its 200 day moving average is $28.73.
Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.06. During the same quarter in the prior year, the business posted ($0.58) earnings per share. On average, equities analysts anticipate that Global Blood Therapeutics will post ($2.48) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/12/j-p-morgan-chase-co-reiterates-overweight-rating-for-global-blood-therapeutics-inc-gbt.html.
In other Global Blood Therapeutics news, Director Deval L. Patrick sold 27,053 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the completion of the sale, the director now directly owns 12,053 shares of the company’s stock, valued at $357,853.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 143,255 shares of the company’s stock, valued at $4,297,650. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Global Blood Therapeutics by 4,675.5% in the first quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock worth $96,503,000 after buying an additional 2,564,008 shares in the last quarter. White Square Capital LLP purchased a new stake in Global Blood Therapeutics during the first quarter worth approximately $53,593,000. Perceptive Advisors LLC raised its stake in Global Blood Therapeutics by 23.3% in the first quarter. Perceptive Advisors LLC now owns 3,858,978 shares of the company’s stock worth $142,203,000 after buying an additional 730,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Global Blood Therapeutics by 40.1% in the first quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after buying an additional 726,366 shares in the last quarter. Finally, Redmile Group LLC raised its stake in Global Blood Therapeutics by 195.3% in the first quarter. Redmile Group LLC now owns 934,343 shares of the company’s stock worth $34,431,000 after buying an additional 617,943 shares in the last quarter. 72.29% of the stock is owned by institutional investors.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.